期刊文献+

185例肝细胞癌临床病理学分析 被引量:3

Clinicopathologic features of hepatocellular carcinoma: an analysis of 185 cases
原文传递
导出
摘要 目的 探讨肝细胞癌(HCC)的临床病理特征与预后的关系.方法 收集185例行手术切除并获得随访的HCC患者的临床资料,男性169例(91.4%),女性16例(8.6%),男女比例为10.6∶1;年龄19~72岁,平均年龄(51.0±11.0)岁.采用Kaplan-Meier法和Cox风险回归模型分析HCC患者临床病理特征与预后的关系.结果 全组患者的术后3年和5年生存率分别为52.0%和38.0%.Kaplan-Meier单因素分析结果显示,肿瘤数目(P=0.000)、肿瘤大小(P=0.025)、组织学结构类型(P=0.000)、核分级(P=0.000)、分化程度(P=0.001)及血管浸润(P=0.000)均与HCC患者的预后明显相关.组织学结构类型中,细梁状型、致密梁状型和假腺样型患者的生存时间差异无统计学意义(P>0.05),但明显高于粗梁状型、实性型和硬化型(P<0.05),硬化型患者的生存时间与实性型的差异无统计学意义(P>0.05),但明显短于其余各型(P<0.05).核分级为1级与2级患者的生存时间差异无统计学意义(P>0.05),3级与4级患者的生存时间差异无统计学意义(P>0.05),但3级患者的生存时间明显短于1、2级(P<0.05).Cox风险回归模型分析结果显示,肿瘤数目(P=0.001)、肿瘤大小(P=0.042)、核分级(P=0.023)和血管浸润情况(P=0.000)是影响HCC患者预后的主要因素.结论 肿瘤数目、肿瘤大小、核分级和血管浸润情况是影响HCC患者预后的主要因素,肿瘤数目越多、肿瘤越大、核分级越高和有血管浸润者的死亡风险越大. Objective To analyze the clinicopathologic features and prognostic factors of hepatocellular carcinoma. Methods Clinicopathological data of 185 cases of hepatocellular carcinoma treated in our hospital between 2000 and 2005 were collected and their follow up information was obtained.The clinicopathological features and prognostic factors were analyzed by Kaplan-Meier and multivariate Cox regression analysis. Results The 185 patients had a median age of 51.0 ± 11.0 ( range, 19-72 ) years.and 5-year postoperational survival rates were 52.0% and 38.0%; respectively. The tumour numbers ( P =0.000), tumor size ( P = 0. 025 ) , histological pattern ( P = 0. 000 ), nuclear features ( P = 0. 000 ),differentiation ( P = 0.001 ) and vascular invasion ( P = 0. 000 ) were significantly correlated with prognosis.The postoperational survival times of patients with thin trabeculae pattern, compact pattern and pseudoglandular pattern were significantly longer than that of thick trabeculae, scirrhous pattern, and solid pattern (P≤0.009). The postoperational survival time of patients with nuclear features grade 1 and 2 was significantly longer than that of grade 3 and 4 ( P = 0. 000). Multivariate Cox regression analysis showed that the tumor number ( P = 0. 001 ), tumor size ( P = 0. 042 ) , nuclear features ( P = 0. 023 ) and vascular invasion ( P = 0. 000) were independent prognostic factors. Conclusion The postoperational survival rate of HCC patients is low. The tumor size, tumor number, differentiation and vascular invasion are major prognostic factors of hepatocellular carcinoma, The higher is the tumor number, tumor size, degree of differentiation and presence of vascular invasion, the higher risk of mortality is.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2010年第8期609-613,共5页 Chinese Journal of Oncology
关键词 肝细胞 预后 临床病理学特征 Carcinoma,hepatocellular Prognosis Clinicopathological features
  • 相关文献

参考文献14

  • 1Bosch FX,Ribes J,Borr(o)s J.Epidemiology of primary liver cancer.Semin Liver Dis,1999,19:271-285.
  • 2Jong-wook L.Global health improvement and WHO:shaping the future.Lancet,2003,362:2083-2088.
  • 3Sherman M.Hepatocellular carcinoma:epidemiology,risk factors,and screening.Semin Liver Dis,2005,25:143-154.
  • 4Zachary DG,Luigi MT.Tumours and tumour-like lesions of the liver//Alastair DB,Bernard CP,Linda DF.Macsween's pathology of the liver.5th ed.Philadephia:Elsevier,2007:777-785.
  • 5Hirohas S,Ishak KG,Kojiro M,et al.Hepatocellular carcinoma//Hamilton SR,Aaltonen LA.Pathology and Genetics of Tumours of the Digestive System.Lyon:IARC Press,2003:164-166.
  • 6Ishak KG,Goodman ZD,Stocker JT.Tumors of the liver an intrahepatic bile ducts.Atlas of tumor pathology,3rd Series.Washington:Armed Forces Institute of Pathology,2001.
  • 7Scheuer PJ.Classification of chronic viral hepatitis:a need for reassessment.J Hepatol,1991,13:372-374.
  • 8Bosch FX,Ribes J,Diaz M,et al.Primary liver cancer:worldwide incidence and trends.Gastroenterology,2004,127:S5-S16.
  • 9Montalto G,Cervello M,Giannitrapani L,et al.Epidemiology,risk factors,and natural history of hepatocellular carcinoma.Ann N Y Acad Sci,2002,963:13-20.
  • 10Michielsen PP,Francque SM,van Dongen JL.Viral hepatitis and hepatocellular carcinoma.World J Surg Oncol,2005,3:27.

二级参考文献2

  • 1Jin-qing Li,Ya-qi Zhang,Wei-zhang Zhang,Yun-fei Yuan,Guo-hui Li. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy[J] 1995,Journal of Cancer Research and Clinical Oncology(6):364~366
  • 2Ken’ichi Wakasa,Masami Sakurai,Jun Okamura,Chikazumi Kuroda. Pathological study of small hepatocellular carcinoma: Frequency of their invasion[J] 1985,Virchows Archiv A Pathological Anatomy and Histopathology(3):259~270

共引文献34

同被引文献21

  • 1韩者艺,吴开春,蒋海萍,申慧琴,时永全,韩英,刘长江,薛妍,刘娜,郭长存,乔泰东,樊代明.电压门控钾通道Kv1.5反义核酸对胃癌细胞SGC7901生长的抑制作用[J].解放军医学杂志,2004,29(9):773-775. 被引量:3
  • 2王朕华,丰有吉,王以政.钾离子通道与肿瘤细胞的关系[J].国外医学(肿瘤学分册),2005,32(10):733-736. 被引量:4
  • 3中华医学会传染病与寄生虫病学分会;中华医学会肝病学分会.病毒性肝炎防治方案[J]中华传染病杂志,2001(01).
  • 4El-Serag HB. Hepatocellular carcinoma[ J]. N Engl J Med, 2011, 365(12) : 1118-1127. DOI: 10.1056/NEJMra1001683.
  • 5Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma [ J ]. Ann N Y Acad Sci, 2002, 963:13-20.
  • 6E1-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma [ J ]. GastroenteroIogy, 2012, 142 (6) : 1264-1273. DOI: 10.1053/j.gastro.2011.12.061.
  • 7Strasak AM, Pfeiffer RM, Klenk J, et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women[J]. Int J Cancer, 2008, 123(8) : 1902-1906. DOI: 10. 1002/ijc.23714.
  • 8Strasak AM, Rapp K, Brant LI, et al. Association of gamma gamma-glutamyhransferase and risk of cancer incidence in men : a prospective study [ J ]. Cancer Res, 2008, 68 (10) : 3970-3977. DOI : 10.1158/0008-5472.
  • 9o- Ju M J, Qiu S J, Fan J, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation[J]. J Gastroenterol, 2009, 44(6) :635-642. DOI: 10. 1007/sOO535-009-0050-x.
  • 10Guiu B, Desehamps F, Boulin M, et al. Serum gamma-glutamyl- transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation [ J ]. Cardiovase Intervent Radiol, 2012, 35 ( 5 ) : 1102-1108. DOI: 10.1007/s00270-011-0293-9.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部